As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.
12 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:
12 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:
Jun '25 |
+/-
%
|
||
Revenue | 529 529 |
56%
56%
|
|
Gross Profit | 455 455 |
53%
53%
|
|
EBITDA | 5.98 5.98 |
123%
123%
|
EBIT (Operating Income) EBIT | 4.48 4.48 |
116%
116%
|
Net Profit | 4.79 4.79 |
147%
147%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
Head office | Bermuda |
CEO | Sanj Patel |
Employees | 315 |
Founded | 2015 |
Website | www.kiniksa.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.